EP0528468A1 - Verwendung von Triclosan zur Herstellung eines Arzneimittels zur Inhibierung der Cyclooxygenase - Google Patents

Verwendung von Triclosan zur Herstellung eines Arzneimittels zur Inhibierung der Cyclooxygenase Download PDF

Info

Publication number
EP0528468A1
EP0528468A1 EP92202287A EP92202287A EP0528468A1 EP 0528468 A1 EP0528468 A1 EP 0528468A1 EP 92202287 A EP92202287 A EP 92202287A EP 92202287 A EP92202287 A EP 92202287A EP 0528468 A1 EP0528468 A1 EP 0528468A1
Authority
EP
European Patent Office
Prior art keywords
triclosan
medicament
cyclo
manufacture
oxygenase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP92202287A
Other languages
English (en)
French (fr)
Other versions
EP0528468B1 (de
Inventor
Franciscus J. Unilever Research Van Der Ouderaa
Diane Unilever Research Cummins
Derek Michael C. Unilever Research Hull
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Unilever PLC
Unilever NV
Original Assignee
Unilever PLC
Unilever NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unilever PLC, Unilever NV filed Critical Unilever PLC
Publication of EP0528468A1 publication Critical patent/EP0528468A1/de
Application granted granted Critical
Publication of EP0528468B1 publication Critical patent/EP0528468B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/27—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/347—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists

Definitions

  • Periodontitis is a general term describing specific diseases affecting the gingiva and the supporting connective tissue and alveolar bone which anchor the teeth in the jaws. Periodontitis causes loss of connective tissue, resorption of alveolar bone and formation of periodontal pockets, and may lead to a loosening of the teeth, and ultimately to the loss of teeth.
  • Periodontal disease is mainly caused by specific anaerobic bacteria in the periodontal pockets.
  • the destruction of the periodontal tissue is primarily caused by the indirect effects mediated by the host's reaction to the bacteria.
  • Bacterial metabolites induce leucocyte chemotaxis which results in the inflammatory cells accumulating at the site of the bacterial challenge.
  • bacterial metabolites induce the production of inflammatory mediators by leucocytic cells, in particular monocytes.
  • local disease mediators such as metabolites of arachidonic acid, e.g. leukotrienes, prostaglandins and thromboxanes.
  • the loss of alveolar bone may be directly induced by pathogenic metabolites of bacteria, in particular proteolyte enzymes.
  • Prostaglandins have been found to be particularly important in the metabolism and destruction of tissue and alveolar bone. Indeed, the production of prostaglandins in the periodontal tissues has been found to be an important mediator of the loss of alveolar bone in the periodontium; patients with periodontal breakdown show an elevated prostaglandin E2 level both in the gingival tissue as well as in the crevicular fluid.
  • Prostaglandins and thromboxanes are formed from arachidonic acid by an enzyme cascade, the first step of which is the cyclo-oxygenation by an enzyme called cyclo-oxygenase.
  • cyclo-oxygenase inhibitors particularly non steroidal anti-inflammatory drugs such as indomethacin and flurbiprofen have been found to markedly reduce the resorption of alveolar bone.
  • Triclosan has a considerable anti-cyclo-oxygenase activity, thus significantly inhibiting the formation of prostaglandins. Inhibiting the biosynthesis of the prostaglandins locally would thereby significantly inhibit or prevent alveolar bone resorption. Triclosan has been shown to be retained by gingival tissue both in vitro and in vivo following topical application.
  • non steroidal anti-inflammatory agent can be selected from various classes of such agents, including indomethacin, ibuprofen, diclofenac and so on.
  • the present invention relates to the use of Triclosan in the manufacture of a medicament for inhibiting prostaglandin-forming cyclo-oxygenase activity. More particularly, it relates to the use of Triclosan in the manufacture of a medicament for preventing or inhibiting alveolar bone resorption. It relates especially to the use of Triclosan as prostaglandin-forming cyclo-oxygenase inhibitor in the manufacture of a medicament for preventing or reducing periodontitis.
  • Triclosan is a well-known anti-bacterial agent, used i.a. in oral compositions to reduce or inhibit the growth of dental plaque. Its use to inhibit cyclo-oxygenase activity to prevent or inhibit alveolar bone resorption or periodontitis has not been indicated in the prior art as far as we know.
  • Triclosan also has anti-bacterial activity, it not only modulates the host response system by inhibiting cyclo-oxygenase activity, but also reduces the microbial challenge, thus having a highly desirable combined, dual effect to prevent or reduce periodontitis.
  • the Triclosan-containing medicament of the present invention can be manufactured in any form, suitable for administering the medicament to achieve the reduction or prevention of periodontitis.
  • Such forms are tablets, capsules, pills, powders, granules, solutions, suspensions, salves, gels, pastes etc.
  • Suitable forms for oral administration are toothpastes, mouthwashes, gels and the like.
  • the amount of Triclosan used in the present invention may vary from 0.0001 - 5, preferably 1% by weight of the medicament.
  • the Triclosan is preferably used in an amount above its MIC-values for certain micro organisms occurring in the pockets, known to contribute to periodontitis such as strains from the genera Actinomyces, Bacteroides, Peptococcus, Peptostreptococeus, Veillonella, Actinobacillus, Eubacteria, Fusobacteria and Liptotrichia, e.g. Bacteroides gingivalis, B. intermedius, Actinobacillus actinomycetemcomitans.
  • the MIC-value of Triclosan for the latter is 0.0005%, and for all the other species between 0.001 and 0.005%.
  • the medicament furthermore may comprise further, conventional ingredients, such as pharmaceutically acceptable carriers like starch, sucrose, polyols, surfactants, water or water/alcohol systems etc.
  • pharmaceutically acceptable carriers like starch, sucrose, polyols, surfactants, water or water/alcohol systems etc.
  • such formulation may contain all the usual dentifrice ingredients.
  • they may comprise particulate abrasive materials such as silicas, aluminas, calcium carbonates, dicalciumphosphates, hydroxyapatites, trimetaphosphates, insoluble hexametaphosphates and so on, usually in amounts between 5 and 60% by weight.
  • humectants such as glycerol, sorbitol, propyleneglycol, lactitol and so on.
  • Surface-active agents may also be included such as anionic, nonionic, amphoteric and zwitterionic synthetic detergents. Examples thereof are sodiumlaurylsulphate, sodium dodecylbenzenesulphonate, sodium mono- and dioctylphosphate, sodiumlauroylsarcosinate.
  • Binders and thickeners such as sodium carboxymethylcellulose, xanthan gum, gum arabic etc. may also be included, as well as synthetic polymers such as polyacrylates, copolymers of polyvinylmethylether with maleic anhydride.
  • Flavours such as peppermint and spearmint oils may also be included, as well as preservatives, opacifying agents, colouring agents, pH-adjusting agents, sweetening agents and so on.
  • anti-bacterial agents such as chlorhexidine, copper-, zinc- and stannous salts, sanguinarine extract, metronidazole; furthermore anti-inflammatory agents such as ibuprofen, flurbiprofen, aspirin, indomethacin etc. may also be included.
  • anti-bacterial agents such as chlorhexidine, copper-, zinc- and stannous salts, sanguinarine extract, metronidazole; furthermore anti-inflammatory agents such as ibuprofen, flurbiprofen, aspirin, indomethacin etc.
  • the amount of zinc salt used may vary from 0.05 to about 10 % by weight, calculated as zinc ion.
  • Anti-caries agents such as sodium- and stannous fluoride, aminefluorides, monosodiumfluorophosphate, casein and casein digests may also be included.
  • Vitamins such as Vitamin C, plant extracts, potassium salts such as potassium citrate and potassium nitrate can also be included.
  • additional anti-bacterial agents are quaternary ammonium compounds such as cetylpyridinium chloride; bis-guanides such as chlorhexidine digluconate, hexetidine, octenidine, alexidine.
  • anti-plaque agents include enzymes such as dextranase and/or mutanase, amyloglucosidase, glucoseoxidase with lactic oxidase, neuro amidases, hydrogenperoxide generating compounds such as potassiumperoxydiphosphate.
  • enzymes such as dextranase and/or mutanase, amyloglucosidase, glucoseoxidase with lactic oxidase, neuro amidases, hydrogenperoxide generating compounds such as potassiumperoxydiphosphate.
  • I50 value is the concentration of inhibitor which gives 50% inhibition of cyclo-oxygenase activity.
  • the cyclo-oxygenase activity was measured at 25°C by monitoring the oxygen consumption as a result of cyclo-oxygenation of the substrate using a Clark oxygen electrode.
  • the cyclo-oxygenase activity of the sample was calculated from the oxygen consumption curve assuming that maximum deflection of the recorder corresponds to 0.26 mM dissolved oxygen in the buffer and that 2 moles of oxygen are consumed per mole of substrate.
  • the linear part of the sigmoid curve of oxygen consumption was used for initial-rate calculations.
  • the experiments were standardised by measuring the activity of the enzyme stock solution before and after each set of kinetic experiments and normalizing results to the mean activity.
  • Neonatal mouse calvaria were isolated with minimum trauma and maintained in a nutrient medium appropriate for cell culture (DMEM + 15 % horse serum) at 270C in 100 % humidity, the medium also containing the materials under test. The pH was maintained in an atmosphere of 5 % CO2. After 24h the medium was discarded, the calvaria were divided into control and test groups, and the medium was replaced with fresh medium containing the materials under test.
  • Prostaglandin E2 PGE2, 10 ⁇ 6M
  • Example 2 The test method of Example 2 was repeated, using thrombin, however, as bone loss stimulator, and using indomethacin as a cyclo-oxygenase inhibitor as control.
  • Example 3 The procedure of Example 3 was repeated, also using zinc citrate as addition.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Amplifiers (AREA)
  • Electrotherapy Devices (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Control Of Motors That Do Not Use Commutators (AREA)
EP92202287A 1991-08-08 1992-07-24 Verwendung von Triclosan zur Herstellung eines Arzneimittels zur Inhibierung der Cyclooxygenase Expired - Lifetime EP0528468B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919117140A GB9117140D0 (en) 1991-08-08 1991-08-08 Treatment of periodontitis
GB9117140 1991-08-08

Publications (2)

Publication Number Publication Date
EP0528468A1 true EP0528468A1 (de) 1993-02-24
EP0528468B1 EP0528468B1 (de) 1996-03-20

Family

ID=10699703

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92202287A Expired - Lifetime EP0528468B1 (de) 1991-08-08 1992-07-24 Verwendung von Triclosan zur Herstellung eines Arzneimittels zur Inhibierung der Cyclooxygenase

Country Status (8)

Country Link
US (1) US5240696A (de)
EP (1) EP0528468B1 (de)
JP (1) JPH05194203A (de)
AT (1) ATE135569T1 (de)
AU (1) AU2081592A (de)
CA (1) CA2075551C (de)
DE (1) DE69209190T2 (de)
GB (1) GB9117140D0 (de)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994026258A1 (en) * 1993-05-13 1994-11-24 Unilever N.V. Oral compositions containing triclosan for the treatment of aphthous ulcers
US5945089A (en) * 1998-11-05 1999-08-31 I-Dent International Corporation Method of treating mucositis
US5998487A (en) * 1998-04-08 1999-12-07 Colgate-Palmolive Company Anti-inflammatory and antibacterial benzyl phenol agents and their use in oral compositions
WO2000006109A1 (de) * 1998-07-30 2000-02-10 Henkel Kommanditgesellschaft Auf Aktien Entzündungshemmende zahnpflegemittel
US6045800A (en) * 1997-10-02 2000-04-04 Lg Chemical Ltd. Composition for preventing or treating periodontal diseases comprising extract from Achyranthis radix or Ulmus cortex
EP0992238A1 (de) * 1998-10-06 2000-04-12 I-Dent International Corporation Verwendung von Triclosan zur Behandlung und Prävention von mukosale und dermatologische Beschwerden
US6440395B1 (en) 1992-06-22 2002-08-27 Barry M. Libin Antiplaque mouth rinse
WO2003061704A2 (en) * 2002-01-23 2003-07-31 Pharmacia & Upjohn Company Combination therapy for the treatment of bacterial infections
EP1508323A1 (de) * 2003-08-20 2005-02-23 Unilever N.V. Verwendung einer zinkhaltigen oralen Zubereitung
WO2007082181A3 (en) * 2006-01-10 2007-09-27 Colgate Palmolive Co Methods of modulating cell surface receptors to prevent or reduce inflammation
US8617523B2 (en) 2009-04-01 2013-12-31 Colgate-Palmolive Company Anti-biofilm carbonate compounds for use in oral care compositions
US8637266B2 (en) 2009-04-01 2014-01-28 Colgate-Palmolive Company Anti bone-loss and anti attachment-loss effects of an oral composition
US8753820B2 (en) 2009-04-01 2014-06-17 Colgate-Palmolive Company Protein biomarkers for soft tissue disease diagnosis and as therapeutic targets for oral care intervention
US9968803B2 (en) 2009-10-29 2018-05-15 Colgate-Palmolive Company Low water stannous fluoride plus zinc citrate dentifrice with improved stability, rheology, and efficacy
US10426752B2 (en) 2009-04-01 2019-10-01 Colgate-Palmolive Company Menthol-derivative compounds and use thereof as oral and systemic active agents

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2979446B2 (ja) * 1991-11-06 1999-11-15 ライオン株式会社 口腔用組成物
US5843409A (en) * 1994-08-08 1998-12-01 Colgate Palmolive Company Two component dentifrice for the treatment of dentinal hypersensitivity
US5807541A (en) * 1996-04-22 1998-09-15 Sepracor, Inc. NSAID/fluoride periodontal compositions and methods
US5958911A (en) * 1996-11-05 1999-09-28 The Research Foundation Of State University Of New York Method of relieving inflammation by using 5-alkylsulfonylsalicylanilides
US5932192A (en) * 1997-04-23 1999-08-03 Colgate-Palmolive Company Lower astringent two component stannous and potassium salt containing dentifrice
US6117859A (en) * 1997-11-04 2000-09-12 The Research Foundation Of State University Of New York Method of relieving chronic inflammation by using 5-alkylsulfonylsalicylanilides
ES2248015T3 (es) * 1999-03-12 2006-03-16 Pfizer Products Inc. Composiciones orales que comprenden una sal de potasio para reducir la sensibilidad del nervio central y de la dentina.
HUP0201914A3 (en) * 1999-04-19 2009-05-28 Unilever Nv Oral care composition
FR2812190B1 (fr) * 2000-07-28 2003-01-31 Oreal Utilisation d'agonistes non prostanoiques des recepteurs des prostaglandines ep-2 et/ou ep-4 comme agent cosmetique permettant d'attenuer, de diminuer ou d'arreter la chute des cheveux et des poils
FR2812192B1 (fr) * 2000-07-28 2003-01-31 Oreal Utilisation d'antagonistes de recepteur des prostaglandines ep-3 comme agent cosmetique permettant d'attenuer, de diminuer ou d'arreter la chute des cheveux et des poils
ES2214135B1 (es) * 2003-02-21 2005-05-01 Laboratorios Kin S.A. Composicion para el tratamiento de la cavidad bucal y utilizaciones correspondientes.
US20060134025A1 (en) * 2004-12-17 2006-06-22 Colgate-Palmolive Company Oral compositions containing extracts of Rosmarinus and related methods
EP1962778B1 (de) * 2005-12-21 2017-08-23 Colgate-Palmolive Company Verbesserte orale zusammensetzungen mit zinkcitrat
US7687650B2 (en) 2006-02-03 2010-03-30 Jr Chem, Llc Chemical compositions and methods of making them
US7897800B2 (en) 2006-02-03 2011-03-01 Jr Chem, Llc Chemical compositions and methods of making them
AU2006337161B2 (en) 2006-02-03 2012-06-07 Obagi Cosmeceuticals Llc Anti-aging treatment using copper and zinc compositions
US7867522B2 (en) 2006-09-28 2011-01-11 Jr Chem, Llc Method of wound/burn healing using copper-zinc compositions
US8273791B2 (en) 2008-01-04 2012-09-25 Jr Chem, Llc Compositions, kits and regimens for the treatment of skin, especially décolletage
CA2750636C (en) 2009-01-23 2017-07-25 Jr Chem, Llc Rosacea treatments and kits for performing them
US8952057B2 (en) 2011-01-11 2015-02-10 Jr Chem, Llc Compositions for anorectal use and methods for treating anorectal disorders
EP2921173A1 (de) 2014-03-21 2015-09-23 Omya International AG Oberflächenreaktives Calciumkarbonat zum Desensibilisieren von Zähnen
JP7412869B2 (ja) * 2016-08-05 2024-01-15 小林製薬株式会社 歯肉ケア剤及びそれを含有する歯肉ケア用口腔用組成物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0161898A2 (de) * 1984-05-09 1985-11-21 Unilever Plc Zahnpflegemittel
EP0295954A2 (de) * 1987-06-18 1988-12-21 Block Drug Company Inc. Präparate zur Behandlung von Beschwerden der Wurzelhaut der Zähne
EP0474597A2 (de) * 1990-09-05 1992-03-11 Ciba-Geigy Ag Arachidonsäurestoffwechselhemmende Diphenylverbindungen und ihre Verwendung in pharmazeutischen Zusammensetzungen
WO1992010994A1 (en) * 1990-12-18 1992-07-09 The Procter & Gamble Company Oral compositions effective against plaque and gingivitis

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2501548A1 (de) * 1974-01-25 1975-07-31 Procter & Gamble Mundbehandlungsmittel
MX3783E (es) * 1975-07-04 1981-07-16 Gaba Ag Procedimiento para la preparacion de composiciones para el tratamiento de enfermedades bucales y dentales
US4358443A (en) * 1980-04-14 1982-11-09 The Research Foundation Of State University Of New York Method and composition for controlling the growth of microorganisms
US4287191A (en) * 1980-04-14 1981-09-01 The Research Foundation Of State University Of New York Novel salicylanilides and microbiocidal compositions and uses thereof
GB2084870B (en) * 1980-10-10 1985-05-09 Muhlemann R Hans Oral compositions containing pyrimidine amine compounds and zinc salts
US4742083A (en) * 1983-08-24 1988-05-03 Lever Brothers Company Method of relieving pain and inflammatory conditions employing substituted salicylamides
US4575457A (en) * 1984-05-24 1986-03-11 American Home Products Corporation Periodontal toothpaste with wound-healing properties
US4664906A (en) * 1984-08-30 1987-05-12 Johnson & Johnson Products Inc. Oral compositions
GB8729564D0 (en) * 1987-12-18 1988-02-03 Unilever Plc Oral compositions
GB8922594D0 (en) * 1989-10-06 1989-11-22 Unilever Plc Oral compositions
US4961924A (en) * 1989-11-15 1990-10-09 Gillette Canada Inc. Stabilized stannous fluoride toothpaste
JPH03266468A (ja) * 1990-03-15 1991-11-27 Nec Corp 電界効果トランジスタ
US5015467A (en) * 1990-06-26 1991-05-14 The Procter & Gamble Company Combined anticalculus and antiplaque compositions
GB9107833D0 (en) * 1991-04-12 1991-05-29 Unilever Plc Treatment of periodontitis

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0161898A2 (de) * 1984-05-09 1985-11-21 Unilever Plc Zahnpflegemittel
EP0295954A2 (de) * 1987-06-18 1988-12-21 Block Drug Company Inc. Präparate zur Behandlung von Beschwerden der Wurzelhaut der Zähne
EP0474597A2 (de) * 1990-09-05 1992-03-11 Ciba-Geigy Ag Arachidonsäurestoffwechselhemmende Diphenylverbindungen und ihre Verwendung in pharmazeutischen Zusammensetzungen
WO1992010994A1 (en) * 1990-12-18 1992-07-09 The Procter & Gamble Company Oral compositions effective against plaque and gingivitis

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AGENTS AND ACTIONS vol. 29, no. 3/4, 1990, pages 232 - 238; S.OFFENBACHER ET AL.: 'Inhibition of human periodontal prostaglandin E2 synthesis with selected agents' *
J.CLIN.PERIODONTOL. vol. 17, no. 8, 1990, pages 570 - 574; C.L.JONES ET AL.: 'Microbiological and clinical effects of a dentifrice containing zinc citrate and Triclosan in the human experimental gingivitis model' *
J.CLIN.PERIODONTOL. vol. 18, no. 6, July 1990, pages 462 - 467; P.D.MARSH: 'Dentifrices containing new agents for the control of plaque and gingivitis: microbiological aspects' *
J.CLIN.PERIODONTOL. vol. 18, no. 6, July 1991, pages 468 - 473; PER GJERMO ET AL.: 'Antibacterial dentifrices' *
R.BERKOW 'The Merck Manual' 1982 , MERCK SHARP & DOHME RESEARCH LABORATORIES , RAHWAY, N.J., USA *

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440395B1 (en) 1992-06-22 2002-08-27 Barry M. Libin Antiplaque mouth rinse
WO1994026258A1 (en) * 1993-05-13 1994-11-24 Unilever N.V. Oral compositions containing triclosan for the treatment of aphthous ulcers
US5500448A (en) * 1993-05-13 1996-03-19 Chesebrough-Pond's Usa Co., Division Of Conopoco, Inc. Recurrent aphthous ulcer treatment method
US6045800A (en) * 1997-10-02 2000-04-04 Lg Chemical Ltd. Composition for preventing or treating periodontal diseases comprising extract from Achyranthis radix or Ulmus cortex
US5998487A (en) * 1998-04-08 1999-12-07 Colgate-Palmolive Company Anti-inflammatory and antibacterial benzyl phenol agents and their use in oral compositions
WO2000006109A1 (de) * 1998-07-30 2000-02-10 Henkel Kommanditgesellschaft Auf Aktien Entzündungshemmende zahnpflegemittel
US6491899B1 (en) 1998-07-30 2002-12-10 Henkel Kommanditgesellschaft Auf Aktien Anti-inflammatory dental care agents
EP0992238A1 (de) * 1998-10-06 2000-04-12 I-Dent International Corporation Verwendung von Triclosan zur Behandlung und Prävention von mukosale und dermatologische Beschwerden
US5945089A (en) * 1998-11-05 1999-08-31 I-Dent International Corporation Method of treating mucositis
WO2003061704A2 (en) * 2002-01-23 2003-07-31 Pharmacia & Upjohn Company Combination therapy for the treatment of bacterial infections
WO2003061704A3 (en) * 2002-01-23 2003-12-18 Upjohn Co Combination therapy for the treatment of bacterial infections
EP1508323A1 (de) * 2003-08-20 2005-02-23 Unilever N.V. Verwendung einer zinkhaltigen oralen Zubereitung
WO2007082181A3 (en) * 2006-01-10 2007-09-27 Colgate Palmolive Co Methods of modulating cell surface receptors to prevent or reduce inflammation
EP2177621A3 (de) * 2006-01-10 2010-09-08 Colgate-Palmolive Company Verfahren zur Modulierung von Zellenoberflächenrezeptoren zur Vermeidung oder Verringerung von Entzündung
US9157914B2 (en) 2006-01-10 2015-10-13 Colgate-Palmolive Company Methods of modulating cell surface receptors to prevent or reduce inflammation
US8617523B2 (en) 2009-04-01 2013-12-31 Colgate-Palmolive Company Anti-biofilm carbonate compounds for use in oral care compositions
US8637266B2 (en) 2009-04-01 2014-01-28 Colgate-Palmolive Company Anti bone-loss and anti attachment-loss effects of an oral composition
US8753820B2 (en) 2009-04-01 2014-06-17 Colgate-Palmolive Company Protein biomarkers for soft tissue disease diagnosis and as therapeutic targets for oral care intervention
US10426752B2 (en) 2009-04-01 2019-10-01 Colgate-Palmolive Company Menthol-derivative compounds and use thereof as oral and systemic active agents
US9968803B2 (en) 2009-10-29 2018-05-15 Colgate-Palmolive Company Low water stannous fluoride plus zinc citrate dentifrice with improved stability, rheology, and efficacy
US10668306B2 (en) 2009-10-29 2020-06-02 Colgate-Palmolive Company Low water stannous fluoride plus zinc citrate dentifrice with improved stability, rheology, and efficacy
US10682532B2 (en) 2009-10-29 2020-06-16 Colgate-Palmolive Company Low water stannous fluoride plus zinc citrate dentifrice with improved stability, rheology, and efficacy
US11147992B2 (en) 2009-10-29 2021-10-19 Colgate-Palmolive Company Low water stannous fluoride plus zinc citrate dentifrice with improved stability, rheology, and efficacy
US11285342B2 (en) 2009-10-29 2022-03-29 Colgate-Palmolive Company Low water stannous fluoride plus zinc citrate dentifrice with improved stability, rheology, and efficacy

Also Published As

Publication number Publication date
EP0528468B1 (de) 1996-03-20
US5240696A (en) 1993-08-31
ATE135569T1 (de) 1996-04-15
DE69209190D1 (de) 1996-04-25
CA2075551A1 (en) 1993-02-09
GB9117140D0 (en) 1991-09-25
AU2081592A (en) 1993-02-11
CA2075551C (en) 1996-05-07
JPH05194203A (ja) 1993-08-03
DE69209190T2 (de) 1996-08-08

Similar Documents

Publication Publication Date Title
US5240696A (en) Treatment of periodontitis
EP0508524B1 (de) Verwendung von Zinkionen zur Behandlung der Periodontitis
RU2388458C2 (ru) Антибактериальная и противовоспалительная композиция для ухода за полостью рта
US20040057908A1 (en) Oral compositions and use thereof
CA2431044A1 (en) Oral compositions and use thereof
US5578295A (en) Oral care compositions comprising certain substituted diphenyl ethers
CN104887538A (zh) 口腔护理产品及其使用和制造方法
EP1070037B1 (de) Entzendungshemmende antibakterielle benzylphenolverbindungen
US5298237A (en) Gel composition for reduction of gingival inflammation and retardation of dental plaque
TW201102060A (en) Anti-biofilm carbonate compounds for use in oral care compositions
JPH05310544A (ja) 抗う蝕および抗歯周病剤
JP2001089383A (ja) 口腔用及び眼科用組成物
US6180599B1 (en) Pharmaceutical composition, containing medium-chain fatty acids as active ingredients, for dental caries and periodontal disease
WO2002002124A1 (fr) Compositions renfermant des esters d'acide ascorbique-acide phosphorique
GB2380407A (en) Oral composition
US4973472A (en) Dental plaque inhibitor
Drake et al. Synergistic effect of pyrophosphate and sodium dodecyl sulfate on periodontal pathogens
WO2023189061A1 (ja) ｄｌ－α－トコフェロール ２－Ｌ－アスコルビン酸リン酸ジエステルアルカリ金属塩含有組成物
JPH08245352A (ja) 口腔用組成物
JPH07133222A (ja) グルコシルトランスフェラ−ゼ阻害剤
JP2005239653A (ja) 口腔用組成物
JP2023148032A (ja) 口腔用組成物
JP2023148028A (ja) 抗歯周病用組成物
JP2001294536A (ja) 歯周病予防・治療剤
WO1993018741A1 (en) Oral care compositions comprising certain substituted diphenyl ethers

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19921119

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI NL PT SE

17Q First examination report despatched

Effective date: 19930621

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI NL PT SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 19960320

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 19960320

Ref country code: ES

Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY

Effective date: 19960320

Ref country code: DK

Effective date: 19960320

Ref country code: BE

Effective date: 19960320

Ref country code: AT

Effective date: 19960320

REF Corresponds to:

Ref document number: 135569

Country of ref document: AT

Date of ref document: 19960415

Kind code of ref document: T

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: E. BLUM & CO. PATENTANWAELTE

REF Corresponds to:

Ref document number: 69209190

Country of ref document: DE

Date of ref document: 19960425

ITF It: translation for a ep patent filed

Owner name: JACOBACCI & PERANI S.P.A.

ET Fr: translation filed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Effective date: 19960620

Ref country code: PT

Effective date: 19960620

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Effective date: 19960731

Ref country code: CH

Effective date: 19960731

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20020702

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20020717

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20020730

Year of fee payment: 11

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030724

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040203

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20030724

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040331

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20050724